Drugs Made In America Acquisition II Corp. (DMII)

Drugs Made In America Acquisition II Corp. is a blank-check (SPAC) company formed to complete a business combination with one or more operating businesses. Its stated focus is evaluating targets in the pharmaceutical sector, consistent with a theme of U.S.-oriented drug manufacturing and related activities. Until a deal closes, it has no significant commercial operations and holds proceeds primarily in trust.

Market
Nasdaq
Sector
Financial Services
Trend
Strong uptrend
Last close
10.19 (+0.05% on the day)
MA50
10.16
MA200
10.06
52-week range
9.87–10.19
Market cap
648.5M USD
P/E
33.93
Dividend yield
0%
Data as of
2026-06-30
Quarterly revenue and earnings, millions of USD
QuarterRevenueYoY %EarningsYoY %
Q2 20250—-0—
Q3 20250—-0.1—
Q4 20250—4.3—
Q1 20260—4.3—
Q2 20260—4.4—

All markets — KeepWinning global stock screener

Other companies on Nasdaq: Consensus Cloud Solutions, Inc. (CCSI), ACNB Corporation (ACNB), Arbutus Biopharma Corporation (ABUS), MiMedx Group, Inc. (MDXG), Annexon, Inc. (ANNX), Village Super Market, Inc. (VLGEA)